Combination pulse therapy with methotrexate and dexamethasone in patients with early rheumatoid arthritis and poor prognostic factors: an open-label randomized trial

Objective: To study the efficiency and tolerance of two pulse therapy regimens: combination pulse therapy with highdose methotrexate (MT) and high-dose dexamethasone and pulse therapy with dexamethasone. Subjects and methods. The trial enrolled 100 patients with early rheumatoid arthritis (RA) treated with two pulse therapy regimens and then followed up for 1 year during standard MT therapy. The efficiency of the treatment was evaluated using the ACR 20/50/70 criteria. The number of swollen and tender joints (SJ and TJ), erythrocyte sedimentation rate, C-reactive protein levels, systemic disease activity and a need for nonsteroidal anti-inflammatory drugs and glucocorticoids were determined. Results and discussion. After 1 month of therapy, the patients of both groups showed significant positive changes in all assessed parameters of RA activity. By this time, after combination pulse therapy with MT and dexamethasone, there was a more significant reduction in the number of SJ, total activity scores given by a patient and a physician, and pain intensity according to the visual analogue scale. By the end of 1and 3-month follow-ups, a 70% improvement was significantly more frequently noted in the combination pulse therapy group than in the monotherapy group. During a subsequent follow-up, the number of TJ and SJ tended to further decrease; however, the group differences were leveled. Evaluation of X-ray progression trends at 12 months of follow-up revealed no significant differences between the patients of the study groups. There were neither differences in the rate of adverse reactions nor severe complications. Conclusion. Combination pulse therapy with MT and dexamethasone was an effective and well tolerated option, the use of which could lower RA activity considerably, accelerate the therapeutic effect of MT, and reduce symptomatic therapy volume in the shortest possible time.

early rheumatoid arthritis, methotrexate, dexamethasone, pulse therapy, intensive therapy, randomized trial

1. <div><p>Kirwan J.R., Bijlsma J.W., Boers M. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007;1:CD006356.</p><p>Smolen J.S., Landewe R., Breedveld F.C. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.</p><p>Van der Veen M.J., Bijlsma J.W. The effect of methylpred-nisolone pulse therapy on methotrexate treatment of rheumatoid arthritis. Clin Rheumatol 1993;12:500-5.</p><p>Weusten B.L.Jacobs J.W.,Bijlsma J.W. Corticosteroid pulse therapy in active rheumatoid arthritis. Semin Arthr Rheum 1993;23:183-92.</p><p>Durez P., Malghem J., Nzeusseu Toukap A. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthr Rheum 2007;56:3919-27.</p><p>Buttgereit F., Brand M.D., Burmester G.R. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol 1999;58:363-8.</p><p>Kroot E.J., Huisman M.A. Dexamethasone: an «old new» glucocorticoid on the horizon! J Rheumatol 2006;33:1201.</p><p>Соловьев С.К., Асеева Е.А., Чикликчи А.С. Синхронная программная интенсивная терапия больных ревматоидным артритом тяжелого течения. Тер арх 2002;745:52-7.</p><p>Furst D.E., Koehnke R., Burmeister L.F. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989;16:313-20.</p><p>Gabriel S., Creagan E., O'Fallon W.M. Treatment of rheumatoid arthritis with higher dose intravenous methotrexate. J Rheumatol 1990;17:460-5.</p><p>Michaels R.M., Nashel D.G., Leonard A. Weekly intravenous methotrexate in the treatment of rheumatoid arthritis. Arthr Rheum 1982;25:339-41.</p><p>Seideman P. Methotrexate the relationship between dose and clinical effect. Br J Rheumatol 1993;32:751-3.</p><p>Васильева Е.А., Маслянский А.Л., Иливанова Е.П. Варианты интенсификации иммуносупрессивной терапии ревматоидного артрита. Науч-практич ревматол 2007;2:30-5.</p><p>Марусенко И.М. Интенсивная терапия при ревматоидном артрите: реальная эффективность или необходимость в отсутствие альтернативы? Совр ревматол 2009;2:29-37.</p><p>Arnett F.C., Edworthy S.M., Bloch D.A. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum 1988;31:315-24.</p><p>Dankert T., Nieman F., Rau F. Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. Rheumatology (Oxford) 1999;38:941-7.</p><p>Бадокин В.В., Корсакова Ю.Л. Интенсивная терапия псориатического артрита. I. Влияние на основные синдромы заболевания. Науч-практич ревматол 2006;4:70-9.</p><p>Насонов Е.Л. Метотрексат. Перспективы применения в ревматологии. М., 2005; 200 с.</p><p>Никишина И.П., Родионовская С.Р. Метотрексат в терапии ювенильного артрита новые возможности повышения эффективности лечения. Фарматека 2008;6:46-51.</p></div><br />